




Advanced Enzyme Technologies Limited

Where ENZYME is Life



This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section before taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company under takes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.



What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.

Company Overview



Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Mission




It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life!

Vision



Our vision at Advanced Enzymes is to become the largest, enzyme-based, value provider to consumers and processors globally!



Amongst Top 15 Global Enzyme Companies



Manufacturing Units - 7

India - 5 USA - 2



R&D Expenses - 3%

R&D Strength - 60+



68+

Enzymes & Probiotics



400+

Proprietary Products



700+

Customers Worldwide



45+

Countries Worldwide Presence



24+

Years of Fermentation Experience



28

Registered Patents



11

Food Enzyme Dossiers filed with EFSA



1

GRAS Dossier filed with US FDA



420

m³ Fermentation Capacity







550+

Employees

Note: Facts & Figures as on 31st March 2018


Note: 2014: as per IGAAP | 2018: as per IndAs





Revenue Breakup ₹ in Million

*YoY Growth



Note: 1. On Consolidated Basis

2. Segmental Revenue excluding excise duty

3. EBITDA is including other income

4. Does not include sales made by evocxx

5. PAT is before minority


6. Segment-wise revenue does not include other operating income

7. Ind AS adjustments are carried out on account of commission and discount.




Q1FY19

Segmental Revenue Split (%)



■ Animal HC ■ Human HC ■ Food ■ Industrial Processing


Geographical Revenue Split (%)



■ Asia (ex-India) ■ Others ■ India ■ Europe ■ USA


Q1FY18

Segmental Revenue Split (%)



■ Animal HC ■ Human HC ■ Food ■ Industrial Processing

Geographical Revenue Split (%)



■ Asia (ex-India) ■ Others ■ India ■ Europe ■ USA

1. On Consolidated Basis

2. Segmental Revenue excluding excise duty




3. EBITDA is including other income

4. Does not include sales made by evoxx

5. PAT is before minority

6. Segment-wise revenue does not include other operating income


7. Ind AS adjustments are carried out on account of commission and discount.



Revenue Breakup ₹ in Million


*YoY Growth

Animal HC




FY18	506
FY17	512

Human HC




FY18	2,892
FY17	2,386

Food



FY18	200
FY17	223

Industrial Processing



FY18	206
FY17	193

Note: 1. On Consolidated Basis

3. EBITDA is including other income

5. PAT is before minority

7. Ind AS adjustments are carried out on account of commission and discount.

2. Segmental Revenue excluding excise duty

4. Does not include sales made by Evoxx


6. Regrouping has been done wherever necessary

8. Segment-wise revenue does not include other operating income




FY18

Segmental Revenue Split (%)



■ Animal HC ■ Human HC ■ Food ■ Industrial Processing


Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA


FY17

Segmental Revenue Split (%)



■ Animal HC ■ Human HC ■ Food ■ Industrial Processing

Geographical Revenue Split (%)



■ Asia (ex- India) ■ Others ■ India ■ Europe ■ USA

Note: 1. On Consolidated Basis

3. EBIDTA is including other income

5. PAT is before minority

7. Ind AS adjustments are carried out on account of commission and discount.

2. Segmental Revenue excluding excise duty

4. Does not include sales made by Evoxx

6. Regrouping has been done wherever necessary

8. Segment-wise revenue does not include other operating income

Profit & Loss (Consolidated) – Q1FY19



₹ in Million except per share

Particulars	Q1FY19 Unaudited	Q4FY18 Audited	Q1FY18 Unaudited	Y-o-Y (%)	FY18 Audited	FY17 Audited	Y-o-Y (%)
Income from Operations	1,043	1,086	756	38	3,957	3,431	15
Expenses	611	650	499	22	2,500	2,050	22
Profit from Operations before Other Income, Finance Costs and Exceptional Item	432	436	257	68	1,457	1,381	6
Other Income	4	6	3	33	14	26	(46)
Profit from ordinary activities before Finance Costs and Exceptional Item	436	442	260	68	1,471	1,407	5
Finance costs	14	45	12	17	81	36	125
Profit from ordinary activities before exceptional item and tax	422	397	248	70	1,390	1,371	1
Profit from ordinary activities before tax	422	397	248	70	1,390	1,371	1
Tax	110	114	85	29	454	441	3
Net Profit for the period	312	283	163	91	936	929	1
Earnings Per Share	2.66	2.44	1.46		8.07	8.27	

Balance Sheet (Consolidated) – FY18




₹ in Million

Particulars	FY18 Audited	FY17 Audited
Assets		
Property, plant and equipment	1,667	1,664
Capital work-in-progress	105	80
Intangible assets	662	270
Goodwill	2,584	2,280
Other non-current assets	143	166
Current assets	2,107	1,382
Assets held for sale	48	48
Total Assets	7,316	5,890
Equity And Liabilities		
Equity share capital	223	223
Other equity	5,368	4,417
Non-controlling interest	226	211
Non-current liabilities	471	386
Current liabilities	987	617
Liabilities classified as held for sale	41	36
Total – Equity and Liabilities	7,316	5,890




₹ in Million


Revenue from Operations




EBIDTA & EBIDTA Margin (%)



PBT & PBT Margin (%)



PAT & PAT Margin (%)




Note: As per IGAAP | FY17 & FY18 - as per IndAs

All numbers are on Consolidated basis


ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax, Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networkth)




Net Working Capital (Days)




Net Worth (₹ mn)



ROE (%) | ROCE (%) | ROIC (%)



Net Debt to Equity (x)



Note: As per IGAAP | FY17 & FY18 – as per IndAs

All numbers are on Consolidated basis

Net working capital days = $\frac{\text{Trade receivables} + \text{inventories} - \text{Trade payables}}{\text{Revenue from operations}} \times 365$

Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent



Stock Data (As on 10th August 2018)

	Market Capitalization (₹)	25,082 mn
	Shares Outstanding	111.6 mn
	Free Float	30.27 %
	Symbol (NSE/ BSE)	ADVENZYMES / 540025
	Average Daily Volume (3 months)	35,985

Stock Chart (As on 10th August 2018)




Source: BSE, NSE, Thomson Reuters

Top 5 Institutional Holders (As on 03rd August 2018)

Institutions	OS (%)
HDFC Asset Management Co. Ltd. (Invst Mgmt)	4.28
First State Investment Management Ltd. (ICVC)	1.58
Reliance Capital Trustee Co. Ltd	1.54
DSP BlackRock Investment Managers Pvt Ltd.	1.07
Pacific Assets Trust Plc	0.54

Shareholding Pattern (%)



■ Promoters ■ Institutions ■ Public

Note: Data mentioned in above chart is as on 30th June 2018



Thank You

Advanced Enzyme Technologies Limited

5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi,
Thane (W) 400 604, India

Tel.: +91-22-4170 3200 | Fax: + 91-22-25835159 | Web:
www.advancedenzymes.com



IR Contact:

Piyush Rathi - Chief Business Officer

Email: investor.realtions@advancedenzymes.com